Results 251 to 260 of about 2,503,709 (341)

Tacrolimus exposure during pregnancy in kidney and liver transplantation recipients: A comparison between whole blood and plasma concentration‐to‐dose ratios

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tacrolimus monitoring is generally performed in whole blood (WB). Most (>85%) of circulating tacrolimus is bound to red blood cells. During pregnancy, WB monitoring might be suboptimal because of physiological changes including increased plasma volume and decreased haematocrit.
Jildau R. Meinderts   +7 more
wiley   +1 more source

SUN-293 LOW-DOSE VALGANCICLOVIR IS AS EFFECTIVE AS THE STANDARD DOSE PROPHYLAXIS FOR CYTOMEGALOVIRUS IN RENAL TRANSPLANT RECIPIENTS

open access: gold, 2020
Rudreshwar Prabakaran   +4 more
openalex   +1 more source

Systemic Complement Activation in Deceased Donors Is Associated With Acute Rejection After Renal Transplantation in the Recipient

open access: yesTransplantation, 2011
J. Damman   +8 more
semanticscholar   +1 more source

Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra   +8 more
wiley   +1 more source

Pregnancy-related maternal and fetal outcomes following renal transplantation: a decade of experience at a tertiary care center in Saudi Arabia. [PDF]

open access: yesBMC Pregnancy Childbirth
Hejazi J   +9 more
europepmc   +1 more source

Long‐term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real‐world cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long‐term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30‐month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Nicola Perrotta   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy